SCHEMBL30329933

SCHEMBL30329933

COc1cc(NC(=O)OCc2ccccc2)cc2c1OCCO2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.57
NPC1 O15118 4/20 0.57
TP53 P04637 3/20 0.57
MAPT P10636 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
TSHR P16473 2/20 0.57
ALDH1A1 P00352 2/20 0.57
ATM Q13315 1/20 0.57
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
HPGD P15428 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
MGLL Q99685 1/20 0.47
PLK1 P53350 1/20 0.46
POLB P06746 2/20 0.46
ROCK2 O75116 1/20 0.46
KDM4E B2RXH2 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CA1 P00915 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL589813 0.80 NPC1 (0.85) RAB9ANPC1TP53MAPTSMN1; SMN2
SCHEMBL22808210 0.77 SMN1; SMN2 (0.63) RAB9ANPC1TP53MAPTSMN1; SMN2
SCHEMBL27943694 0.74 MGLL (0.56) RAB9ANPC1TP53MAPTSMN1; SMN2
SCHEMBL22808220 0.73 TP53 (0.56) RAB9ANPC1TP53MAPTSMN1; SMN2
SCHEMBL28498351 0.73 ALDH1A1 (0.52) RAB9ANPC1TP53MAPTSMN1; SMN2
SCHEMBL9872046 0.73 MGLL (0.55) RAB9ANPC1TP53MAPTSMN1; SMN2
SCHEMBL3038608 0.72 MGLL (0.58) RAB9ANPC1TP53MAPTSMN1; SMN2
SCHEMBL8116943 0.72 TSHR (0.61) RAB9ANPC1TP53MAPTSMN1; SMN2
SCHEMBL28831371 0.72 PLK1 (0.57) RAB9ANPC1TP53MAPTSMN1; SMN2
SCHEMBL30330025 0.72 TP53 (0.52) RAB9ANPC1TP53MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2024-11-07 US disclosed
EP-4416143-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-08-21 EP disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF EHMT1, EHMT2, SHMT1 RAB9A 3332/4885NPC1 2169/4885TP53 1064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.